GlobeNewswire

Partners Justin Watts and Matthew Shade Bolster WilmerHale's IP Litigation Practice in London

Dela

LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- WilmerHale today announced that Justin Watts, PhD, and Matthew Shade, PhD, have joined the firm as partners in its London office, strengthening WilmerHale's position as a firm of choice for complex patent litigation in the United Kingdom and for clients seeking an effective global strategy for their intellectual property disputes.

Dr. Watts, a first-chair patent litigator with deep experience in international disputes including competition matters, and Dr. Shade, a skilled practitioner and former patent examiner in the European Patent Office, come to WilmerHale from a Magic Circle firm, where Dr. Watts was the head of the firm's UK IP litigation practice. Together they bring more than 30 years of combined practice, with experience in a wide range of technologies, including cell phones, pharmaceutical products, semiconductors and aero engines."

"Justin and Matthew are an impressive duo who will substantially strengthen our international patent litigation capabilities," said Susan Murley, co-managing partner of WilmerHale. "Their experience with high-stakes IP litigation work and ability to manage complex international patent disputes will benefit our life sciences and tech clients alike."

"The opportunity to join WilmerHale allows us to be a part of a firm that boasts the most esteemed IP litigation practice in the United States," said Dr. Watts. "Matthew and I are looking forward to joining the WilmerHale team and contributing our UK and EU expertise to extend the ways in which clients can rely upon WilmerHale for well-coordinated and comprehensive guidance in global patent litigation matters."

WilmerHale's IP Litigation Practice features a premier litigation team backed by the academic and industry experience of more than 100 lawyers and technology specialists with scientific or technical degrees. WilmerHale's lawyers have tried major cases in US federal district courts from coast to coast, before the US International Trade Commission, and in Germany and the United Kingdom. The firm's lawyers also regularly represent clients in patent appeals before the US Supreme Court and the Federal Circuit. Since the first year the title of IP Litigation Department of the Year was awarded in 2004, The American Lawyer has honored WilmerHale twice and a finalist six times in this biennial contest. 

Mark Selwyn, co-chair of WilmerHale's IP Litigation Practice, added, "It is with great pride that we welcome Justin and Matthew. They bring a superb track record of success and commitment to legal excellence, and they will further enhance our ability to offer clients the finest representation for their global IP litigation disputes." 

Biographical Information

Dr. Justin Watts

Justin Watts, a patent litigator, was most recently a partner in the IP and information technology practices of a Magic Circle firm, where he was the head of the firm's UK IP litigation practice. Dr. Watts has handled complex, multinational disputes, often involving the intersection of antitrust and intellectual property. He has appeared before UK courts and high courts of Northern Ireland and Singapore, and has coordinated international patent litigation in the US, Germany and the Netherlands. His clients span a range of industries from pharmaceutical and medical device to technology, media and communications.

Dr. Watts is a highly regarded practitioner, earning consistent recognition by industry publications such as Chambers UK and The Legal 500 UK, by which he has been cited as "one of the best and most strategic litigators in the field."

Before his legal career began in 1994, Dr. Watts worked in satellite communications engineering. He earned his BA in electrical sciences and his PhD in optoelectronics from the University of Cambridge, and his diploma in IP law and practice, with commendation, from the University of Bristol.

Dr. Matthew Shade

Matthew Shade was most recently a patent litigator at a Magic Circle firm, where he was a member of the firm's intellectual property and information technology practices since 2007. His work focuses on complex multijurisdictional patent cases, and he often deals with the interface of intellectual property and antitrust law. Dr. Shade has practiced before the English courts and the European Patent Office. His clients span industries from pharmaceuticals and medical devices to consumer electronics.

Previously, Dr. Shade managed the patent department of a high-tech spin-out from Cambridge University and he was a patent examiner at the European Patent Office. He earned his BS, with honors, from the University of Manchester, and his PhD in chemistry from the University of Oxford. He is a registered solicitor in England and Wales and a European patent attorney.

About Wilmer Cutler Pickering Hale and Dorr LLP

WilmerHale provides legal representation across a comprehensive range of practice areas that are critical to the success of its clients. The law firm's leading Intellectual Property, Litigation/Controversy, Regulatory and Government Affairs, Securities and Transactional Departments participate in some of the highest-profile legal and policy matters. With a staunch commitment to public service, the firm is renowned as a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia. For more information, please visit www.wilmerhale.com.

Lauren C. Bishop
WilmerHale
lauren.bishop@wilmerhale.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: WilmerHale via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum